BK0025 Animal Health II
- 677.197
- -0.843-0.12%
Tianjin Ringpu Bio-Technology Raises $207 Million From Private Placement
09:47 PM EST, 11/18/2021 (MT Newswires) -- Tianjin Ringpu Bio-Technology (SHE:300119) raised 1.32 billion yuan ($207.1 million) from the sale of shares through a private placement, according to a bou
A picture to understand the 2021 report of pre-science biology.
Securities Star data Center News, pre-Science Biology 2021 reported that the company's main income was 545 million yuan, up 53.49% from the same period last year; the net profit was 286 million yuan, up 56.45% from the same period last year; deducting 279 million yuan from non-net profit, up 53.96% from the same period last year; debt ratio 14.03%, investment income 2.5633 million yuan, financial expenses-29.2556 million yuan, gross profit margin 81.69%. There are four new shareholders in this period. China China Construction Bank Corporation Co., Ltd.-Castrol Agricultural Industry Equity Securities Investment Fund holds 2.216913 million shares, accounting for the proportion of outstanding shares.
Sept. 17 Shengda biological limit analysis: vitamin, feed concept hot stock
Securities Star data center news, Shengda biological trading closed, closing price 18.61 yuan. The stock rose by the limit at 10:33 and opened the limit three times. The closing capital was 19.6708 million yuan, accounting for 0.62% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 41.6363 million yuan, the net inflow of hot capital was 33.146 million yuan, and the net outflow of retail funds was 22.1671 million yuan. In the past 5 days, the capital flow is shown in the following table: this unit is a vitamin, feed concept hot unit, the same day vitamin concept rose 1.12%, feed concept rose 0.26%. The investment logic of this unit
Sept. 16 Shengda biological limit analysis: feed, vitamin concept hot stock
Securities Star data center news, Shengda biological trading closed, closing price 16.92 yuan. The stock rose by the daily limit at 10:25, but did not open the limit. The closing capital was 38.7706 million yuan, accounting for 1.34% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 25.4953 million yuan, the net inflow of hot capital was 27.2923 million yuan, and the net outflow of retail funds was 15.7212 million yuan. In the past 5 days, the capital flow is shown in the following table: this unit is a feed, vitamin concept hot unit, the same day feed concept rose 2.96%, vitamin concept rose 1.74%. The investment logic of this unit
A new wave of A-shares has emerged, and many shares have doubled!
The three major A-share indices collectively opened higher and lower. In the afternoon, the index continued to consolidate at a low level. Individual stocks in the two markets were red and green, with a turnover exceeding 1.5 trillion yuan, exceeding 1 trillion yuan for 33 consecutive trading days. On the sector side, stimulated by news, Beijing Stock Exchange concept stocks such as the New Third Board Selection and Venture Capital soared, and wind power stocks continued to rise; high-ranking stocks such as military, coal, chemicals, non-ferrous metals, lithium batteries, photovoltaics, etc., fell sharply; up to the point where lithium ore, rare earths, titanium dioxide, and small metals resource stocks fell and stopped in batches; up to the point where stocks of lithium ore, rare earths, titanium dioxide, small metals, etc. In the market, the Shanghai Index fell 0.43% to close at 3,581 points; the Shenzhen Index fell 0.68% to close at 142179 points; The GEM index fell 1.
Biological shares are proposed to be increased by 900 million yuan, and the actual controller will be changed to Zhang Xianyu and Zhang Jing father and daughter.
On July 8th, Capital State learned that Biological shares (600201.SH) of A-share companies issued a pre-plan for a non-public offering of A-shares in 2021. The company plans to raise no more than 900 million yuan to supplement the working capital, the issuance object is Inner Mongolia Jinyu Biological Holdings Co., Ltd. (hereinafter referred to as "Biological Holdings"), this issue will lead to a change of control of the company. After the completion of the fixed increase, the proportion of biological holding shares will increase, and by adjusting the composition of the company's board of directors, the company will change from a non-controlling shareholder to a controlling shareholder, and the controlling shareholder will be biological holding. Biological holding holds 5% of the company's shares.